AADN score: Predicting response to transarterial chemoembolization, sintilimab and lenvatinib in patients with hepatocellular carcinoma

doi:10.3748/wjg.v31.i48.113856

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 48

This Article

(44)

(65)

(0)

(10)

(1)

(910)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastroenterol. Dec 28, 2025; 31(48): 113856
Published online Dec 28, 2025. doi: 10.3748/wjg.v31.i48.113856

Full Size Figure Download Figure

Figure 3 The prognosis of both the training cohort and the validation cohort based on the AADN score. A: The Kaplan-Meier overall survival curves for the training cohort classify patients into low-risk, intermediate-risk, and high-risk groups according to their AADN score (log-rank P < 0.0001); B: The Kaplan-Meier progression-free survival curves for the training cohort classify patients into low-risk, intermediate-risk, and high-risk groups according to their AADN score (log-rank P < 0.0001); C: The Kaplan-Meier overall survival curves for the validation cohort classify patients into low-risk, intermediate-risk, and high-risk groups according to their AADN score (log-rank P < 0.0001); D: The Kaplan-Meier progression-free survival curves for the validation cohort classify patients into low-risk, intermediate-risk, and high-risk groups according to their AADN score (log-rank P < 0.0001).

Citation: Zhang X, Liao MJ, Ren LY, Qin WY, Mu SW, She SP, Fei R, Cong X, Zhou YP, Chen DB, Chen HS. AADN score: Predicting response to transarterial chemoembolization, sintilimab and lenvatinib in patients with hepatocellular carcinoma. World J Gastroenterol 2025; 31(48): 113856
URL: https://www.wjgnet.com/1007-9327/full/v31/i48/113856.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i48.113856

Zhang X, Liao MJ, Ren LY, Qin WY, Mu SW, She SP, Fei R, Cong X, Zhou YP, Chen DB, Chen HS. AADN score: Predicting response to transarterial chemoembolization, sintilimab and lenvatinib in patients with hepatocellular carcinoma. World J Gastroenterol 2025; 31(48): 113856 [PMID: 41480328 DOI: 10.3748/wjg.v31.i48.113856]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.